Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade.
2001; National Institutes of Health; Volume: 61; Issue: 12 Linguagem: Inglês
Autores
Takushi Kurashige, Yuji Noguchi, Takashi Saika, Toshiro Ono, Yasuhiro Nagata, Achim A. Jungbluth, Gerd Ritter, Yao Tseng Chen, Elisabeth Stockert, Tomoyasu Tsushima, Hiromi Kumon, Lloyd J. Old, Eiichi Nakayama,
Tópico(s)Monoclonal and Polyclonal Antibodies Research
ResumoNY-ESO-1 mRNA expression in transitional cell carcinoma was investigated by reverse transcription-PCR and immunohistochemistry. NY-ESO-1 mRNA was detected in 20 of 62 (32%) tumor specimens. There was a correlation between NY-ESO-1 expression and tumor grade: 0 of 4 (0%) grade 1 (G1), 6 of 26 (23%) grade 2 (G2), and 14 of 32 (44%) grade 3 (G3) tumors were NY-ESO-1 mRNA positive. Immunohistochemical analysis using NY-ESO-1-specific monoclonal antibody ES121 showed that 2 of 14 NY-ESO-1 mRNA-expressing G3 tumors were positive for NY-ESO-1. No NY-ESO-1 staining was observed in the panel of 30 G1 or G2 tumor specimens, including 6 NY-ESO-1 mRNA-positive cases. Sera from an expanded panel of 124 patients with transitional cell carcinoma were tested for the presence of NY-ESO-1 antibody. Seropositivity was observed in 9 of 72 (12.5%) patients with G3 tumors, whereas none of 52 patients with G1 or G2 tumors produced antibody against NY-ESO-1. In the 9 positive patients with NY-ESO-1 antibody, 4 had muscular invasive tumors, and 5 had carcinoma in situ.
Referência(s)